Bayer’s $2.45 Billion Bet on Eye Disease Meets $7.25 Billion Roundup Reckoning as June Deadlines Converge

Bayer Q1 earnings beat on 4.1% revenue growth and 9% EBITDA rise, but free cash flow turns negative due to legal payouts. Two critical events—opt-out deadline and Supreme Court ruling—will shape glyphosate litigation.

Bayer’s first-quarter earnings delivered a solid operational beat, but the real tension lies in the calendar. Over the next 60 days, two legal events — a class-action settlement opt-out deadline and a Supreme Court ruling — will determine whether the company can finally loosen the grip of glyphosate litigation, even as it spends heavily to build a new revenue line in ophthalmology.

Q1 Numbers Cut Both Ways

The group’s top-line performance offered genuine encouragement. Revenue reached €13.405 billion in the first three months of 2026, up 4.1 percent on a currency- and portfolio-adjusted basis. Underlying profitability jumped even more: EBITDA before special items climbed 9.0 percent to €4.453 billion, a figure that sits well above what many analysts had penciled in given the persistent legal overhang.

Crop Science drove most of that growth. Sales rose 6.8 percent to €7.558 billion, boosted by the soybean seed-and-traits business and a one-off from the termination of a licensing deal with Corteva in North America, which contributed roughly €448 million. The division’s margin improvement prompted UBS to lift its 2026 earnings forecast, with analyst Matthew Weston keeping a “Buy” rating and a €52 price target on the stock.

But the cash flow statement told a different story. Free cash flow swung to minus €2.320 billion, almost entirely because of payouts to resolve PCB and glyphosate claims. Legal settlements alone accounted for a net outflow of €2.002 billion in the quarter. That hemorrhage is the price Bayer pays for operating in the shadow of Roundup.

The Two-Headed Legal Clock

Attention now focuses on two parallel tracks. In Missouri, a judge has given preliminary approval to a proposed $7.25 billion settlement that would cover both current and future claims from individuals who developed non-Hodgkin lymphoma after exposure to glyphosate-based herbicides. Class members have until 4 June 2026 to opt out of the deal, which would stretch payments over as long as 21 years. Bayer retains the right to walk away if too many claimants choose to pursue individual lawsuits.

Meanwhile, the Supreme Court is weighing Monsanto v. Durnell. Oral arguments took place on 27 April, and the justices are expected to rule by the end of June. At stake is whether federal pesticide-warning requirements preempt state-law claims — a question that could gut a large chunk of the more than 100,000 pending cases. JPMorgan analyst Richard Vosser estimates the decision could affect around 80 percent of glyphosate lawsuits. The hearing offered no clear winner: Chief Justice John Roberts and Justice Neil Gorsuch pushed back on Bayer’s arguments, but other justices appeared to give the company’s position serious consideration.

A favorable ruling would weaken the warning-label claims that form the backbone of much of the litigation. A loss, by contrast, would make the proposed settlement even more expensive to manage.

A Strategic Counterweight: Perfuse Therapeutics

Amid the legal noise, Bayer has signed a deal to acquire Perfuse Therapeutics for up to $2.45 billion. The upfront payment is $300 million, with the remainder tied to development, regulatory, and commercial milestones. The prize is PER-001, a Phase II candidate for ischemic eye diseases including glaucoma and diabetic retinopathy.

The transaction fits squarely into Bayer’s ophthalmology strategy. Its current franchise relies heavily on Eylea, which is losing patent protection in key markets. Perfuse offers a chance to broaden the pipeline before biosimilar competition erodes Eylea’s contribution. Barclays described the acquisition as a sensible move to strengthen the eye-care portfolio beyond the Eylea patent cycle, reiterating a €48 target. JPMorgan, with a €50 target and “Overweight” rating, seconded that view.

The deal still requires antitrust clearance and Perfuse shareholder approval, but it signals that management is willing to deploy capital on growth even as legal bills mount.

Stock in the Middle

Bayer shares closed Friday at €37.72, down 0.97 percent on the day but still up 2.00 percent for the week. Over 30 days, the stock has fallen 7.41 percent, reflecting the uncertainty ahead. On a 12-month view, however, the gain stands at 64.79 percent – a reminder that the market has already priced in some resolution of the glyphosate saga.

Looking ahead, the schedule is unforgiving. The 4 June opt-out deadline for the class settlement is followed by the Supreme Court decision expected before July. A fairness hearing on the settlement is set for 9 July. If the legal headlines turn positive, the Perfuse acquisition and the underlying earnings momentum could finally break Bayer’s valuation logjam. If they do not, the cash drain will keep the stock stuck in the same narrow range it has occupied for months.